PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials. Biomedical Research and Therapy, [S. l.], v. 10, n. 12, p. 6090–6102, 2023. DOI: 10.15419/bmrat.v10i12.851. Disponível em: https://preservation.bmrat.org/index.php/BMRAT/article/view/851.. Acesso em: 15 nov. 2024.